Cargando…

Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML

Recently, novel drugs like venetoclax plus 5-azacytidine (VA) were reported to have promising efficacy in refractory acute myeloid leukemia (AML). However, there are still some cases presented with novel drugs resistance, and its genetics composition and clinical phenotype are urging to study. We de...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, JingHan, Ye, Xingnong, Fan, Cuihua, Zhou, Jie, Luo, Shuna, Jin, Jingxia, Chen, Dan, Zheng, Yan, Wu, Cai, Zhu, Xiaoqiong, Jin, Jie, Huang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687845/
https://www.ncbi.nlm.nih.gov/pubmed/33292606
http://dx.doi.org/10.1186/s40364-020-00246-9